Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | IDH1 | O75874 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078869 | 1.00 | MEN1 (0.54) | MEN1KMT2AAKR1C3PKMPRMT1 | |
| SCHEMBL6078878 | 0.99 | MEN1 (0.55) | MEN1KMT2AAKR1C3PKMPRMT1 | |
| SCHEMBL6078621 | 0.99 | MEN1 (0.55) | MEN1KMT2AAKR1C3PKMPRMT1 | |
| SCHEMBL6079410 | 0.99 | MEN1 (0.55) | MEN1KMT2AAKR1C3PKMPRMT1 | |
| SCHEMBL6079569 | 0.99 | MEN1 (0.55) | MEN1KMT2AAKR1C3PKMPRMT1 | |
| SCHEMBL7630246 | 0.95 | MEN1 (0.62) | MEN1KMT2AAKR1C3PKMCA2 | |
| SCHEMBL6078231 | 0.95 | MEN1 (0.56) | MEN1KMT2AAKR1C3PKMPRMT1 | |
| SCHEMBL6428822 | 0.88 | PRMT1 (0.56) | PRMT1IDH1CA2LMNASMN1; SMN2 | |
| SCHEMBL6078872 | 0.88 | MEN1 (0.54) | MEN1KMT2AAKR1C3PKMPRMT1 | |
| SCHEMBL6078471 | 0.88 | MEN1 (0.72) | MEN1KMT2ACA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071231-B2 | Naphthalene ureas as glucose uptake enhancers | TELIK, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1181271-B1 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK INC (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20030135063-A1 | Novel naphthalene ureas as glucose uptake enhancers | SPEVAK WAYNE R (US) | 2003-07-17 | — | — | US | disclosed |
| US-6458998-B1 | NAPHTHALENEUREAS AS ANTIDIABETIC AGENTS | TELIK, INC. | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135063-A1 | Novel naphthalene ureas as glucose uptake enhancers | GPR119, SLC2A8, SLC2A1 | MEN1 3696/4885KMT2A 4632/4885AKR1C3 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.